We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-13.46%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$627M
AUM Growth
-$205M
Cap. Flow
-$88.2M
Cap. Flow %
-14.06%
Top 10 Hldgs %
25.67%
Holding
102
New
6
Increased
38
Reduced
34
Closed
11

Top Buys

Rank Stock Value
1
CI icon
Cigna
CI
+$15.4M
2
HUM icon
Humana
HUM
+$14.8M
3
PFE icon
Pfizer
PFE
+$14.2M
4
MCK icon
McKesson
MCK
+$11M
5
AMGN icon
Amgen
AMGN
+$10.4M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$20.3M
2
JNJ icon
Johnson & Johnson
JNJ
+$18.6M
3
UNH icon
UnitedHealth
UNH
+$10.1M
4
RAD
Rite Aid Corporation
RAD
+$9.6M
5
CVS icon
CVS Health
CVS
+$9.15M

Sector Composition

Rank Sector Weight
1 Healthcare 91.99%
2 Financials 2.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRK icon
51
Merck
MRK
$318B
$4.94M 0.79%
104,800
-167,680
-62% -$8.91M
COO icon
52
Cooper Companies
COO
$14.5B
$4.91M 0.78%
132,000
-32,000
-20% -$1.33M
MDVN
53
DELISTED
MEDIVATION, INC.
MDVN
$4.84M 0.77%
114,000
+22,000
+24% +$1.09M
HTWR
54
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$4.55M 0.73%
87,000
+71,300
+454% +$5.42M
RVNC
55
DELISTED
Revance Therapeutics, Inc.
RVNC
$4.4M 0.7%
148,000
-24,000
-14% -$729K
RAD
56
DELISTED
Rite Aid Corporation
RAD
$4.04M 0.64%
33,250
-57,600
-63% -$9.6M
VTRS icon
57
Viatris
VTRS
$18.9B
$4.03M 0.64%
100,000
+17,000
+20% +$948K
CLVS
58
DELISTED
Clovis Oncology, Inc.
CLVS
$3.95M 0.63%
43,000
-17,765
-29% -$1.54M
IOVA icon
59
Iovance Biotherapeutics
IOVA
$2.87B
$3.94M 0.63%
683,108
+127,108
+23% +$990K
CYBX
60
DELISTED
CYBERONICS INC
CYBX
$3.46M 0.55%
57,000
-43,000
-43% -$2.7M
IONS icon
61
Ionis Pharmaceuticals
IONS
$9.4B
$3.23M 0.52%
80,000
-14,000
-15% -$725K
KITE
62
DELISTED
Kite Pharma, Inc.
KITE
$3.17M 0.51%
57,000
-9,000
-14% -$566K
CLDX icon
63
Celldex Therapeutics
CLDX
$3.28B
$3.11M 0.5%
19,667
+6,534
+50% +$1.85M
PTLA
64
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$3.03M 0.48%
71,000
-5,000
-7% -$241K
PODD icon
65
Insulet
PODD
$9.79B
$2.85M 0.45%
110,000
+20,000
+22% +$607K
ELGX
66
DELISTED
Endologix Inc
ELGX
$2.81M 0.45%
22,900
+5,000
+28% +$679K
ARIA
67
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$2.51M 0.4%
430,000
-20,000
-4% -$154K
OREX
68
DELISTED
Orexigen Therapeutics, Inc.
OREX
$2.51M 0.4%
118,900
+40,000
+51% +$1.37M
ATXS
69
DELISTED
Astria Therapeutics
ATXS
$2.43M 0.39%
5,007
+583
+13% +$416K
ESPR
70
DELISTED
Esperion Therapeutics
ESPR
$2.36M 0.38%
100,000
-12,000
-11% -$753K
MGNX icon
71
MacroGenics
MGNX
$257M
$2.31M 0.37%
107,959
– –
HALO icon
72
Halozyme
HALO
$12.2B
$2.31M 0.37%
172,000
– –
CPHD
73
DELISTED
Cepheid Inc
CPHD
$2.31M 0.37%
51,000
– –
OMCL icon
74
Omnicell
OMCL
$1.68B
$2.3M 0.37%
74,000
– –
RIGL icon
75
Rigel Pharmaceuticals
RIGL
$750M
$2.29M 0.36%
92,500
– –
1 2
3
4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2015 Portfolio in Review

As of Q3 2015, Rhenman & Partners Asset Management held 102 positions worth $627M, down 25% from $833M the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $88.2M in Q3 2015, closing 11 positions and reducing 34 holdings. Its most notable exit was Biogen, an estimated $20.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 77% a quarter earlier, followed by Financials.

Against the trend, Rhenman & Partners Asset Management opened a new position in Cigna worth $14.3M.

  • Rhenman & Partners Asset Management's largest Q3 2015 buy was Cigna: 105,900 shares worth $14.3M.
  • Rhenman & Partners Asset Management added most to McKesson in Q3 2015, an estimated $11M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2015 reduction was UnitedHealth, cutting an estimated $10.1M.
  • Rhenman & Partners Asset Management fully exited Biogen in Q3 2015, selling an estimated $20.3M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 26% of its $627M portfolio in Q3 2015.
  • Rhenman & Partners Asset Management opened 6 new positions and closed 11 in Q3 2015.
  • Rhenman & Partners Asset Management's portfolio value fell 25% quarter-over-quarter to $627M.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2015, filed 26 Oct 2015.